Clearline Capital’s Heron Therapeutics HRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.77M | Sell |
857,166
-202,745
| -19% | -$420K | 0.07% | 83 |
|
|
2025
Q1 | $2.33M | Sell |
1,059,911
-750,572
| -41% | -$1.65M | 0.14% | 79 |
|
|
2024
Q4 | $2.77M | Sell |
1,810,483
-416,029
| -19% | -$637K | 0.37% | 65 |
|
|
2024
Q3 | $4.43M | Buy |
2,226,512
+731,246
| +49% | +$1.46M | 0.19% | 71 |
|
|
2024
Q2 | $5.23M | Sell |
1,495,266
-1,280,938
| -46% | -$4.48M | 0.14% | 65 |
|
|
2024
Q1 | $7.69M | Sell |
2,776,204
-3,292,350
| -54% | -$9.12M | 0.38% | 39 |
|
|
2023
Q4 | $10.3M | Sell |
6,068,554
-81,288
| -1% | -$138K | 0.63% | 28 |
|
|
2023
Q3 | $6.33M | Buy |
6,149,842
+3,483,858
| +131% | +$3.59M | 0.54% | 50 |
|
|
2023
Q2 | $3.09M | Buy |
2,665,984
+576,692
| +28% | +$669K | 0.18% | 60 |
|
|
2023
Q1 | $3.15M | Buy |
2,089,292
+1,064,510
| +104% | +$1.61M | 0.48% | 55 |
|
|
2022
Q4 | $2.56M | Buy |
+1,024,782
| New | +$2.56M | 0.46% | 58 |
|
|
2020
Q2 | – | Sell |
-47,667
| Closed | -$560K | – | 80 |
|
|
2020
Q1 | $560K | Buy |
+47,667
| New | +$560K | 0.26% | 55 |
|
|
2019
Q3 | – | Sell |
-16,920
| Closed | -$315K | – | 57 |
|
|
2019
Q2 | $315K | Sell |
16,920
-22,416
| -57% | -$417K | 0.15% | 47 |
|
|
2019
Q1 | $961K | Hold |
39,336
| – | – | 0.5% | 33 |
|
|
2018
Q4 | $1.02M | Buy |
39,336
+8,577
| +28% | +$222K | 0.7% | 44 |
|
|
2018
Q3 | $974K | Buy |
+30,759
| New | +$974K | 0.58% | 39 |
|